Ameliorating agent for blood-brain barrier dysfunction

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9617324
APP PUB NO 20150166626A1
SERIAL NO

14378323

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

To provide a peptide which can be produced and processed more readily compared with prothymosin α , which is conventionally known, or a peptide thereof and has an activity at a level equivalent to or higher than that of prothymosin α or a peptide thereof. The present invention provides an ameliorating agent for blood-organ barrier dysfunction, a therapeutic agent for diseases associated with blood-organ barrier dysfunction or ischemic diseases or a nerve cell death inhibitor, each comprising, as an active ingredient, a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or a peptide having substantially the same function as that of the aforementioned peptide.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NAGASAKI UNIVERSITYNAGASAKI

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ueda, Hiroshi Nagasaki, JP 546 6423

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 11, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00